Updated on 6 November 2013
Dr Douglas has held various roles at CSL since 2005, including head of R&D project management and program director, influenza, where she had oversight of the licensure of CSL's influenza vaccine in the US and Europe, development and registration of CSL's prototype pandemic H5N1 vaccine, successful negotiation of pandemic vaccine supply and funding contracts with Australia, Singapore and New Zealand and development of CSL's Pandemic Preparedness Action Plan.
Before joining CSL, Dr Douglas was the CEO of the CRC for Discovery of Genes for Common Human Diseases. Prior to this she was a senior researcher at the Walter and Eliza Hall Institute of Medical Research and the Royal Melbourne Hospital.
Dr Douglas holds a Bachelor of Science with first class honours, Master of Health Administration and a PhD in Forensic Medicine. She is also a graduate of the Australian Institute of Company Directors.
"I am delighted to be able to contribute to the work of Australia's premier biotechnology industry body: both at a personal level and to continue to bring CSL's support to the industry's growth," she said.
The AGM also marked the retirement of AusBiotech director Dr Meera Verma, who joined the board in October 2010 when working with Hospira and later became proprietor of Headland Vision. Dr Verma served as the chair of the Risk and Audit Sub-Committee (RaSC) from 2011.